1.Li, D. D.; Li, Q. H., SARS-CoV-2: vaccines in the pandemic era. Mil Med Res 2021, 8, 1, 10.1186/s40779-020-00296-y.
2.WHO Coronavirus Disease (COVID-19) Dashboard (https://covid19.who.int/). https://covid19.who.int/
3.Dan, J. M.; Mateus, J.; Kato, Y.; Hastie, K. M.; Yu, E. D.; Faliti, C. E.; Grifoni, A.; Ramirez, S. I.; Haupt, S.; Frazier, A.; Nakao, C.; Rayaprolu, V.; Rawlings, S. A.; Peters, B.; Krammer, F.; Simon, V.; Saphire, E. O.; Smith, D. M.; Weiskopf, D.; Sette, A.; Crotty, S., Immunological memory to SARS-CoV-2 assessed for up to eight months after infection. bioRxiv 2020, 10.1101/2020.11.15.383323.
4.Grifoni, A.; Weiskopf, D.; Ramirez, S. I.; Mateus, J.; Dan, J. M.; Moderbacher, C. R.; Rawlings, S. A.; Sutherland, A.; Premkumar, L.; Jadi, R. S.; Marrama, D.; de Silva, A. M.; Frazier, A.; Carlin, A. F.; Greenbaum, J. A.; Peters, B.; Krammer, F.; Smith, D. M.; Crotty, S.; Sette, A., Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 2020, 181, 1489-1501 e1415, 10.1016/j.cell.2020.05.015.
5.Sette, A.; Crotty, S., Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021, 184, 861-880, 10.1016/j.cell.2021.01.007.
6.Jarjour, N. N.; Masopust, D.; Jameson, S. C., T Cell Memory: Understanding COVID-19. Immunity 2021, 54, 14-18, 10.1016/j.immuni.2020.12.009.
7.Bonifacius, A.; Tischer-Zimmermann, S.; Dragon, A. C.; Gussarow, D.; Vogel, A.; Krettek, U.; Godecke, N.; Yilmaz, M.; Kraft, A. R. M.; Hoeper, M. M.; Pink, I.; Schmidt, J. J.; Li, Y.; Welte, T.; Maecker-Kolhoff, B.; Martens, J.; Berger, M. M.; Lobenwein, C.; Stankov, M. V.; Cornberg, M.; David, S.; Behrens, G. M. N.; Witzke, O.; Blasczyk, R.; Eiz-Vesper, B., COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity 2021, 54, 340-354 e346, 10.1016/j.immuni.2021.01.008.
8.Post, N.; Eddy, D.; Huntley, C.; van Schalkwyk, M. C. I.; Shrotri, M.; Leeman, D.; Rigby, S.; Williams, S. V.; Bermingham, W. H.; Kellam, P.; Maher, J.; Shields, A. M.; Amirthalingam, G.; Peacock, S. J.; Ismail, S. A., Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS One 2020, 15, e0244126, 10.1371/journal.pone.0244126.
9.Krammer, F.; Simon, V., Serology assays to manage COVID-19. Science 2020, 368, 1060-1061, 10.1126/science.abc1227.
10.Ashour, H. M.; Elkhatib, W. F.; Rahman, M. M.; Elshabrawy, H. A., Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens 2020, 9, 10.3390/pathogens9030186.
11.Pfizer: Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study; (2020).
12.Summary of product characteristics. Comirnaty concentrate for dispersion for injection. COVID-19 mRNA Vaccine.,
13.Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine. Updated 31 March 2021 (https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/information-for-healthcare-professionals-on-pfizerbiontech-covid-19-vaccine).
14.Wang, J.; Peng, Y.; Xu, H.; Cui, Z.; Williams, R. O., 3rd, The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech 2020, 21, 225, 10.1208/s12249-020-01744-7.
15.Mathieu, E.; Ritchie, H.; Ortiz-Ospina, E.; Roser, M.; Hasell, J.; Appel, C.; Giattino, C.; Rodes-Guirao, L., A global database of COVID-19 vaccinations. Nat Hum Behav 2021, 10.1038/s41562-021-01122-8.
16.Polack, F. P.; Thomas, S. J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J. L.; Perez Marc, G.; Moreira, E. D.; Zerbini, C.; Bailey, R.; Swanson, K. A.; Roychoudhury, S.; Koury, K.; Li, P.; Kalina, W. V.; Cooper, D.; Frenck, R. W., Jr.; Hammitt, L. L.; Tureci, O.; Nell, H.; Schaefer, A.; Unal, S.; Tresnan, D. B.; Mather, S.; Dormitzer, P. R.; Sahin, U.; Jansen, K. U.; Gruber, W. C.; Group, C. C. T., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020, 383, 2603-2615, 10.1056/NEJMoa2034577.
17.Hassan, A. O.; Case, J. B.; Winkler, E. S.; Thackray, L. B.; Kafai, N. M.; Bailey, A. L.; McCune, B. T.; Fox, J. M.; Chen, R. E.; Alsoussi, W. B.; Turner, J. S.; Schmitz, A. J.; Lei, T.; Shrihari, S.; Keeler, S. P.; Fremont, D. H.; Greco, S.; McCray, P. B., Jr.; Perlman, S.; Holtzman, M. J.; Ellebedy, A. H.; Diamond, M. S., A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. Cell 2020, 182, 744-753 e744, 10.1016/j.cell.2020.06.011.
18.Hansen, J.; Baum, A.; Pascal, K. E.; Russo, V.; Giordano, S.; Wloga, E.; Fulton, B. O.; Yan, Y.; Koon, K.; Patel, K.; Chung, K. M.; Hermann, A.; Ullman, E.; Cruz, J.; Rafique, A.; Huang, T.; Fairhurst, J.; Libertiny, C.; Malbec, M.; Lee, W. Y.; Welsh, R.; Farr, G.; Pennington, S.; Deshpande, D.; Cheng, J.; Watty, A.; Bouffard, P.; Babb, R.; Levenkova, N.; Chen, C.; Zhang, B.; Romero Hernandez, A.; Saotome, K.; Zhou, Y.; Franklin, M.; Sivapalasingam, S.; Lye, D. C.; Weston, S.; Logue, J.; Haupt, R.; Frieman, M.; Chen, G.; Olson, W.; Murphy, A. J.; Stahl, N.; Yancopoulos, G. D.; Kyratsous, C. A., Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 2020, 369, 1010-1014, 10.1126/science.abd0827.
19.Rydyznski Moderbacher, C.; Ramirez, S. I.; Dan, J. M.; Grifoni, A.; Hastie, K. M.; Weiskopf, D.; Belanger, S.; Abbott, R. K.; Kim, C.; Choi, J.; Kato, Y.; Crotty, E. G.; Kim, C.; Rawlings, S. A.; Mateus, J.; Tse, L. P. V.; Frazier, A.; Baric, R.; Peters, B.; Greenbaum, J.; Ollmann Saphire, E.; Smith, D. M.; Sette, A.; Crotty, S., Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 2020, 183, 996-1012 e1019, 10.1016/j.cell.2020.09.038.
20.Poon, M. M. L.; Farber, D. L., Lasting memories of SARS-CoV-2 infection. J Exp Med 2021, 218, 10.1084/jem.20210210.
21.Report to JCVI on estimated efficacy of a single dose of Pfizer BioNTech (BNT162b2 mRNA) vaccine and of a single dose of ChAdOx1 vaccine (AZD1222)
22.Angyal, A.; Longet, S.; Moore, S.; Payne, R. P.; Harding, A.; Tipton, T.; Rongkard, P.; Ali, M.; Hering, L. M.; Meardon, N.; Austin, J.; Brown, R.; Skelly, D.; al., e., T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. . Available at SSRN: https://ssrn.com/abstract=3812375 or http://dx.doi.org/10.2139/ssrn.3812375 2021,
23.Krammer, F.; Srivastava, K.; Alshammary, H.; Amoako, A. A.; Awawda, M. H.; Beach, K. F.; Bermudez-Gonzalez, M. C.; Bielak, D. A.; Carreno, J. M.; Chernet, R. L.; Eaker, L. Q.; Ferreri, E. D.; Floda, D. L.; Gleason, C. R.; Hamburger, J. Z.; Jiang, K.; Kleiner, G.; Jurczyszak, D.; Matthews, J. C.; Mendez, W. A.; Nabeel, I.; Mulder, L. C. F.; Raskin, A. J.; Russo, K. T.; Salimbangon, A. T.; Saksena, M.; Shin, A. S.; Singh, G.; Sominsky, L. A.; Stadlbauer, D.; Wajnberg, A.; Simon, V., Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med 2021, 10.1056/NEJMc2101667.
24.Saadat, S.; Tehrani, Z. R.; Logue, J.; Newman, M.; Frieman, M. B.; Harris, A. D.; Sajadi, M. M., Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA 2021, 10.1001/jama.2021.3341.
25.Ebinger, J. E.; Fert-Bober, J.; Printsev, I.; Wu, M.; Sun, N.; Prostko, J. C.; Frias, E. C.; Stewart, J. L.; Van Eyk, J. E.; Braun, J. G.; Cheng, S.; Sobhani, K., Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med 2021, 10.1038/s41591-021-01325-6.
26.Mazzoni, A.; Di Lauria, N.; Maggi, L.; Salvati, L.; Vanni, A.; Capone, M.; Lamacchia, G.; Mantengoli, E.; Spinicci, M.; Zammarchi, L.; Kiros, S. T.; Rocca, A.; Lagi, F.; Colao, M. G.; Parronchi, P.; Scaletti, C.; Turco, L.; Liotta, F.; Rossolini, G. M.; Cosmi, L.; Bartoloni, A.; Annunziato, F., First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in recovered COVID-19 subjects. J Clin Invest 2021, 10.1172/JCI149150.
27.Gobbi, F.; Buonfrate, D.; Moro, L.; Rodari, P.; Piubelli, C.; Caldrer, S.; Riccetti, S.; Sinigaglia, A.; Barzon, L., Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses 2021, 13, 10.3390/v13030422.
28.FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines. January 04, 2021.
29.Doria-Rose, N.; Suthar, M. S.; Makowski, M.; O'Connell, S.; McDermott, A. B.; Flach, B.; Ledgerwood, J. E.; Mascola, J. R.; Graham, B. S.; Lin, B. C.; O'Dell, S.; Schmidt, S. D.; Widge, A. T.; Edara, V. V.; Anderson, E. J.; Lai, L.; Floyd, K.; Rouphael, N. G.; Zarnitsyna, V.; Roberts, P. C.; Makhene, M.; Buchanan, W.; Luke, C. J.; Beigel, J. H.; Jackson, L. A.; Neuzil, K. M.; Bennett, H.; Leav, B.; Albert, J.; Kunwar, P.; m, R. N. A. S. G., Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med 2021, 10.1056/NEJMc2103916.
30.European Centre for Disease Prevention and Control. Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination. 29 March 2021. ECDC: Stockholm, 2021.,
31.Dan, J. M.; Mateus, J.; Kato, Y.; Hastie, K. M.; Yu, E. D.; Faliti, C. E.; Grifoni, A.; Ramirez, S. I.; Haupt, S.; Frazier, A.; Nakao, C.; Rayaprolu, V.; Rawlings, S. A.; Peters, B.; Krammer, F.; Simon, V.; Saphire, E. O.; Smith, D. M.; Weiskopf, D.; Sette, A.; Crotty, S., Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021, 371, 10.1126/science.abf4063.
32.Chia, W. N.; Zhu, F.; Ong, S. W. X.; Young, B. E.; Fong, S. W.; Le Bert, N.; Tan, C. W.; Tiu, C.; Zhang, J.; Tan, S. Y.; Pada, S.; Chan, Y. H.; Tham, C. Y. L.; Kunasegaran, K.; Chen, M. I.; Low, J. G. H.; Leo, Y. S.; Renia, L.; Bertoletti, A.; Ng, L. F. P.; Lye, D. C.; Wang, L. F., Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe 2021, 10.1016/S2666-5247(21)00025-2.
33.Skelly, D. T.; Harding, A. C.; al., e., Two doses of SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 variants of concern than does natural infection. Available at Research Square: https://doi.org/10.21203/rs.3.rs-226857/v2 2021,
34.Reynolds, C. J.; Pade, C.; Gibbons, J. M.; Butler, D. K.; Otter, A. D.; Menacho, K.; Fontana, M.; Smit, A.; Sackville-West, J. E.; Cutino-Moguel, T.; Maini, M. K.; Chain, B.; Noursadeghi, M.; Brooks, T.; Semper, A.; Manisty, C.; Treibel, T. A.; Moon, J. C.; Valdes, A. M.; McKnight, Á.; Altmann, D. M.; Boyton, R., Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science 2021, 10.1126/science.abh1282.
35.Blain, H.; Tuaillon, E.; Gamon, L.; Pisoni, A.; Miot, S.; Picot, M. C.; Bousquet, J., Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose. JAMA 2021, 10.1001/jama.2021.6042.
36.Monin, L.; Laing, A. G.; Muñoz-Ruiz, M.; McKenzie, D. R.; del Molino del Barrio, I.; Alaguthurai, T.; Domingo-Vila, C.; Hayday, T. S.; Graham, C.; Seow, J.; Abdul-Jawad, S.; Kamdar, S.; Harvey-Jones, E.; Graham, R.; Cooper, J.; Khan, M.; Vidler, J.; Kakkassery, H.; Sinha, S.; Davis, R.; Dupont, L.; Francos Quijorna, I.; O'Brien-Gore, C.; Lee, P. L.; Eum, J.; Conde Poole, M.; Joseph, M.; Davies, D.; Wu, Y.; Swampillai, A.; North, B. V.; Montes, A.; Harries, M.; Rigg, A.; Spicer, J.; Malim, M. H.; Fields, P.; Patten, P.; Di Rosa, F.; Papa, S.; Tree, T.; Doores, K. J.; Hayday, A. C.; Irshad, S., Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. The Lancet Oncology 2021, 10.1016/s1470-2045(21)00213-8.
37.Abu-Raddad, L. J.; Chemaitelly, H.; P., C.; Malek, J. A.; Ahmed, A. A.; Mohamoud, Y. A.; al., e., SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks. medRxiv [Preprint]. 2021. DOI: doi.org/10.1101/2021.01.15.21249731. Available at: https://www.medrxiv.org/content/10.1101/2021.01.15.21249731v 2021,
38.Perez, G.; Banon, T.; Gazit, S.; Moshe, S. B.; Wortsman, J.; Grupel, D.; al., e., A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report. medRxiv [Preprint]. 2021. DOI: 10.1101/2021.03.06.21253051. Available at: https://www.medrxiv.org/content/10.1101/2021.03.06.21253051v1,
39.Keehner, J.; Horton, L. E.; Pfeffer, M. A.; Longhurst, C. A.; Schooley, R. T.; Currier, J. S.; Abeles, S. R.; Torriani, F. J., SARS-CoV-2 Infection after Vaccination in Health Care Workers in California. N Engl J Med 2021, 384, 1774-1775, 10.1056/NEJMc2101927.
40.White, E. M.; Yang, X.; Blackman, C.; Feifer, R. A.; Gravenstein, S.; Mor, V., Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents. New England Journal of Medicine 2021, 10.1056/NEJMc2104849.